Proto-Oncogene Proteins c-ret
"Proto-Oncogene Proteins c-ret" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.
Descriptor ID |
D051096
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.087 D12.776.395.550.200.188.500 D12.776.543.131.500 D12.776.543.750.630.217 D12.776.624.664.700.194
|
Concept/Terms |
Proto-Oncogene Proteins c-ret- Proto-Oncogene Proteins c-ret
- Proto Oncogene Proteins c ret
- c-ret, Proto-Oncogene Proteins
- Receptor Tyrosine Kinase RET
- ret Proto-Oncogene Proteins
- Proto-Oncogene Proteins, ret
- ret Proto Oncogene Proteins
- Proto-Oncogene Protein c-ret
- Proto Oncogene Protein c ret
- c-ret, Proto-Oncogene Protein
- c-ret Protein
- Proto-Oncogene Protein Ret
- Proto Oncogene Protein Ret
- Ret, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-ret".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-ret".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-ret" by people in this website by year, and whether "Proto-Oncogene Proteins c-ret" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 4 | 4 |
1996 | 0 | 8 | 8 |
1997 | 0 | 2 | 2 |
1998 | 0 | 3 | 3 |
1999 | 0 | 3 | 3 |
2000 | 0 | 2 | 2 |
2001 | 0 | 3 | 3 |
2003 | 0 | 4 | 4 |
2004 | 0 | 3 | 3 |
2005 | 1 | 4 | 5 |
2006 | 0 | 2 | 2 |
2007 | 2 | 6 | 8 |
2008 | 3 | 5 | 8 |
2009 | 3 | 2 | 5 |
2010 | 3 | 4 | 7 |
2011 | 3 | 2 | 5 |
2012 | 2 | 2 | 4 |
2013 | 2 | 1 | 3 |
2014 | 3 | 3 | 6 |
2015 | 2 | 3 | 5 |
2016 | 3 | 1 | 4 |
2017 | 10 | 3 | 13 |
2018 | 5 | 2 | 7 |
2019 | 1 | 1 | 2 |
2020 | 7 | 3 | 10 |
2021 | 6 | 2 | 8 |
2022 | 0 | 9 | 9 |
2023 | 1 | 8 | 9 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-ret" by people in Profiles.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332.
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.
-
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.
-
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300252.
-
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.
-
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors. Ann Oncol. 2023 10; 34(10):946-948.
-
Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ. 2023 Jun 05; 23(1):410.
-
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacol Ther. 2023 02; 242:108344.